<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363900">
  <stage>Registered</stage>
  <submitdate>22/03/2013</submitdate>
  <approvaldate>5/04/2013</approvaldate>
  <actrnumber>ACTRN12613000358741</actrnumber>
  <trial_identification>
    <studytitle>Azacitidine use in elderly patients (over 65) with high risk myelodysplasia/acute myeloid leukaemia.</studytitle>
    <scientifictitle>The effect of subcutaneous azacitidine on overall survival using the alternate regimen of 75mg/m2/day for 3 days/week (Monday, Wednesday, Friday) for 2 weeks each month in elderly patients (over 65 years old) with high risk myelodysplasia/acute myeloid leukaemia.</scientifictitle>
    <utrn> U1111-1140-9478</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>myelodysplasia</healthcondition>
    <healthcondition>acute myeloid leukaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with high risk myelodysplasia/acute myeloid leukaemia administered azacitidine 75mg/m2 subcutaneously 3 times a week (Monday, Wednesday, Friday) for two consecutive weeks every 4 weeks until unacceptable toxicity, failure of therapy to show improvement in cytopenia, or disease progression/death.</interventions>
    <comparator>Uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>% mean survival</outcome>
      <timepoint>18 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Haematological improvement in at least one cytopenia</outcome>
      <timepoint>4-18 months
Monthly assessment of cytopenias.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Decreased transfusion requirement.</outcome>
      <timepoint>4-18 months
Ongoing assessment of transfusion required. For example, if the gap between transfusions moves from 2 weeks to 3 weeks, this is an improvement. Each participant has the record of the transfusion requirement updated each time they are transfused (variable time between participants)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>&gt;65 years old
Diagnosis of high-risk myelodysplasia or acute myeloid leukaemia on bone marrow biopsy.</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Azacitidine use contraindicated.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/04/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Illawarra Private Cancer Care &amp; Research Centre - Wollongong</hospital>
    <postcode>2500 - Wollongong</postcode>
    <postcode>2217 - Kogarah</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Illawarra Private Cancer Care Centre</primarysponsorname>
    <primarysponsoraddress>35 Denison St
Wollongong
NSW 2500</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Southern Haematology and Cancer Research Institute</fundingname>
      <fundingaddress>35 Denison St
Wollongong
NSW 2500</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is evaluating the effect of less frequent azacitidine treatment in elderly patients with high risk myelodysplasia/acute myeloid leukaemia. Who is it for? You may be eligible to join this study if you are aged over 65 years and have been diagnosed with high risk myelodysplasia or acute myeloid leukaemia on bone marrow biopsy. Trial details: All participants in this trial will received the drug azacitidine at a dose of 75mg/m2 three times a week (Monday, Wednesday, Friday) for two consecutive weeks every 4 weeks. Participants will be assessed for up to 18 months post treatment in order to evaluate survival and response to treatment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Wollongong and the Illawarra Shoalhaven Local Health District Health and Medical HREC</ethicname>
      <ethicaddress>Research Services Office
Building 20, Level 1
University of Wollongong,
Northfields Ave
Wollongong NSW 2522</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>25/03/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Rajeev Ramakrishna</name>
      <address>Illawarra Private Cancer Care Centre
35 Denison St
Wollongong
NSW 2500</address>
      <phone>+61242299400</phone>
      <fax />
      <email>sshaematology@gmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>William Alexander</name>
      <address>Illawarra Private Cancer Care Centre
35 Denison St
Wollongong
NSW 2500</address>
      <phone>+61242299400</phone>
      <fax />
      <email>sshaematology@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>William Alexander</name>
      <address>Illawarra Private Cancer Care Centre
35 Denison St
Wollongong
NSW 2500</address>
      <phone>+61242299400</phone>
      <fax />
      <email>sshaematology@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>William Alexander</name>
      <address>Illawarra Private Cancer Care Centre
35 Denison St
Wollongong
NSW 2500</address>
      <phone>+61242299400</phone>
      <fax />
      <email>sshaematology@gmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>